The FDA lifted the clinical hold on Neuroderm's subcutaneously delivered Parkinson's candidates, paving the way for more studies of the liquid formulations of levodopa and carbidopa in the second half of this year. In response to the Friday morning news, the company's stock ended the day up more than 10%.
Getting drugs into the brain is one of the biggest challenges in medical research. Now a group of investigators at the University of North Carolina in Chapel Hill say they found an ideal method, hijacking tiny "bubbles" produced by cells and turning them into a delivery vehicle for a potent Parkinson's medication.
Exosomes are the small fat and protein bubbles that cells create to manage waste and transport materials. Naturally, then, the vesicles are ideal for use in drug delivery, and researchers are using exosomes to deliver antioxidants to the brain--bypassing the challenging blood-brain barrier--to treat Parkinson's disease.
Two months removed from winning European approval for its lead drug, Italian biotech Newron Pharmaceuticals has raised $25.5 million to jump-start its pipeline assets, pushing forward with a stable of CNS candidates.
Levodopa is often the drug of choice to mitigate the symptoms of Parkinson's disease, but getting the treatment into the bloodstream can be challenging because of the erratic muscle movement in Parkinson's patients' digestion systems. AbbVie's gel-based Duopa is designed to improve absorption of levodopa in the small intestine, and researchers at the University of Kentucky recently demonstrated long-term safety and efficacy of the delivery method.
A team of investigators at the Florida branch of Scripps Research Institute says that a little-understood enzyme known as serum glucocorticoid kinase 1 could play a role in preventing or treating Parkinson's disease.
The FDA wants to know how price comparisons in advertising affect people's perceptions of drug quality. The agency's Office of Prescription Drug Promotion is planning a new study to assess how diabetes patients and their doctors react to direct-to-consumer advertisements that feature price info.
In a small study, an early-stage Parkinson's treatment from partners Prothena and Roche reduced levels of a protein with ties to the memory-destroying disease, sending the former company's shares up about 40%.
Portuguese researchers are developing and testing a smart, portable system to manage Parkinson's disease in real time. The so-called Rempark system has been tested on more than 50 volunteers from Spain, Italy, Ireland and Israel, reports Medical Xpress. Unlike previous studies, these outpatients lived at home and used the device in real-world conditions.
Kees Been has banked the $20 million round needed to move a bold new development program for delaying or preventing Parkinson's toward the clinic. And the veteran biotech CEO at the helm of Lysosomal Therapeutics Inc. is moving forward with a group of high-profile backers in his corner.